Fla. cancer center pays $12 million in fraud settlement

Mar 23, 2010

The U.S. Department of Justice announced yesterday that a large multispecialty physician group in Florida has agreed to pay $12 million to settle allegations that it submitted false reimbursement claims for radiation oncology treatments to federal healthcare agencies.

Click here to read the rest of the article.

Prostate Imaging

What is the best timing for PET scans after radiotherapy?

March 28, 2025

Radiation Therapy Suite 400

ASTRO vice chair highlights momentum for ROCR Act

March 19, 2025

Consolidation reigns in radiation oncology

March 7, 2025

Breast Cancer3 400

ASTRO: Shorter radiation course safe for breast reconstruction

October 2, 2024

What is the best timing for PET scans after radiotherapy?

Men should have prostate-specific membrane antigen (PSMA) PET scans about eight months after undergoing external beam radiotherapy for prostate cancer.

March 28, 2025

Prostate Imaging

ASTRO vice chair highlights momentum for ROCR Act

By Amerigo Allegretto

Chris Corso, MD, PhD, from ASTRO discusses why the ROCR Act is needed to stabilize reimbursement for radiation oncologists in the U.S.

March 19, 2025

Radiation Therapy Suite 400

Consolidation reigns in radiation oncology

Solo practices in radiation oncology dropped significantly between 2015 and 2023 while the number of large practices increased by more than half.

March 7, 2025

ASTRO: Shorter radiation course safe for breast reconstruction

By Amerigo Allegretto

Research presented at the ASTRO annual meeting shows that a shorter course of postmastectomy radiation combined with breast reconstruction is safe.

October 2, 2024

Breast Cancer3 400

ASTRO: Timing key to adding immunotherapy to chemoradiation

By Amerigo Allegretto

Timing may be key when adding immunotherapy to chemoradiation for lung cancer treatment.

October 1, 2024

ASTRO: Black patients voice distrust in medical research

Spiritual beliefs and a distrust of clinical research may partly explain why Black patients choose not to participate in cancer trials.

September 30, 2024

ASTRO: IMRT and proton therapy equally effective for prostate cancer

Intensity-modulated radiation therapy (IMRT) and proton therapy offer equally high quality of life and tumor control for people with prostate cancer.

September 30, 2024

Prostate Imaging

ASTRO: Lu-177 dotatate shows promise for treating meningioma patients

By Kate Madden Yee

A radiopharmaceutical therapy that lengthens progression-free survival for patients with neuroendocrine cancer could help treat meningioma sufferers.

September 30, 2024

ASTRO: Brain cancer patients treated by radiation recoup cognitive function

By Kate Madden Yee

Patients with brain metastases who experience cognitive side effects after radiation therapy appear to eventually regain cognitive function.

September 30, 2024

Brain Puzzle Dementia

Bone marrow disorders associated with SARs in Lutathera patients

Pretreatment bone marrow disorders may predict which patients are at risk for severe adverse reactions (SARs) when treated with lutetium-177 DOTATATE.

July 15, 2024

2024 07 11 Sa Rs Patients Lu 177 Dotatate Voter

The rise of theranostics: Part 5 -- Advice from center administrators

Want to launch theranostics at your hospital and cancer center? An SNMMI 2024 session provided key planning steps.

July 12, 2024

Nuclear medicine technologist and theranostics practice administrator Dmitry Beyder (left) and Vikas Prasad, MD, PhD (right), lead the theranostics center at Barnes-Jewish Hospital/Washington University in Saint Louis, MO. Image courtesy of Washington University.

Risk factor for blood disorders identified in PRRT patients

Researchers have identified a risk factor that may be involved in potentially fatal blood disorders in patients undergoing peptide receptor radionuclide therapy (PRRT).

July 12, 2024

Page 1 of 462